Clinical trials: Nutrition Disorders
Obesity, Overweight
ORBERA365 Post-Marketing Clinical Follow-up Study
A prospective, multicenter, open-label, post-approval study of the safety and effectiveness of ORBERA36 as a 12-month adjunct to weight reduction for obese adults (BMI ≥ 27 kg/m2 and BMI ≤ 50 kg/m2) or for pre-surgical weight…
- Trial name
- NCT04362774
- Testing
- ORBERA365
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Apollo Endosurgery, Inc.
Obesity, Diabetes Mellitus Type 2
Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus
The purpose of this study is to explore the mode of action of topiramate in the treatment of obese and diabetic patients by testing association between genetic variations within candidate genes or chromosomes (thread like…
- Trial name
- NCT00304603
- Testing
- No intervention
- Volunteers
- 1,145 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pregnancy, Obesity
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
This is an observational cohort study using administrative insurance claims data. The aim of this non-interventional study (NIS) is to compare maternal, fetal and infant outcomes of women exposed to Wegovy during pregnancy to a…
- Conditions
- Pregnancy, Obesity, Overweight
- Trial name
- NCT05503927
- Testing
- No Intervention
- Where
- 2 sites in United States
- Volunteers
- 2,701 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study of LY3457263 in Obese Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants.
- Trial name
- NCT05582096
- Testing
- LY3457263, Tirzepatide
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pregnancy, Obesity
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
This is an observational, prospective Wegovy (semaglutide 2.4 milligram [mg]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy…
- Conditions
- Pregnancy, Obesity, Overweight
- Trial name
- NCT05872022
- Testing
- No Intervention
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 728 people
- Sponsor
- Novo Nordisk A/S
Overweight , Obesity
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic overweight or obese participants.
- Trial name
- NCT07791537
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity
Gastric Electrical Stimulation (GES) for the Treatment of Obesity
The purpose of this feasibility study is to provide safety data on the implantable Exilis gastric electrical stimulation (GES) system, to individually adjust stimulation parameters to levels that are comfortable for implanted…
- Trial name
- GES (NCT01823705)
- Testing
- Exilis Implantable Gastric Electrical Stimulation (GES)
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 32 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Pre-diabetes, Diabetes
Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics
The trial will test whether the Alive multi-channel delivery health behavior program can positively affect weight and glucose level in pre-diabetics.
- Conditions
- Pre-diabetes, Diabetes, Obesity
- Trial name
- NCT01479062
- Testing
- Alive-PD, Usual Care
- Where
- United States
- Volunteers
- 339 people
- Sponsor
- Berkeley Analytics, Inc.
Obesity
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
- Trial name
- NCT07285902
- Testing
- HRS9531 injection, Semaglutide Injection
- Where
- 2 sites in China
- Volunteers
- 572 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Women
Lactobacillus Gasseri and Hormonal Regulation in Obese Women
To evaluate the regulatory effect of Lactobacillus gasseri LG08 formula on visceral fat metabolism and sex hormone balance in obese women.
- Trial name
- NCT07502404
- Testing
- Probiotic, Maltodextrin
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus)
Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function
This is an open-label, non-randomized study to assess how DA-302168S is absorbed, distributed, metabolized, and eliminated after a single oral dose.
- Trial name
- NCT07877038
- Testing
- DA-302168S
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Overweight or Obesity
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.
- Trial name
- NCT07532655
- Testing
- SYH2082 Injection
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Diabete Mellitus, Hypertension
Faisalabad Initiative of Research and Management of NCDs
The burden of noncommunicable diseases (NCDs) continues to rise globally, and they have become the leading cause of morbidity and mortality, accounting for over 70% of deaths worldwide¹.
- Conditions
- Diabete Mellitus, Hypertension, Hypercholerolemia, Obesity (Disorder)
- Trial name
- FIRM-NCD (NCT07676214)
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Obese, Healthy
The Safety, Tolerability and Pharmacokinetic Study of RAY1225
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225
- Trial name
- NCT05835752
- Testing
- RAY1225
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Undernutrition
Effects of Oral Nutritional Supplementation in Children at Risk of Undernutrition
This prospective, randomized, controlled study will evaluate the effects of oral nutritional supplementation plus dietary counseling versus dietary counseling alone in children at nutritional risk.
- Trial name
- NCT05239208
- Testing
- Oral Nutrition Supplement (ONS) Group, Control Group
- Where
- Vietnam
- Volunteers
- 330 people
- Sponsor
- Abbott Nutrition
Overweight, Obesity
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity.
- Trial name
- NCT06916065
- Testing
- Eloralintide and Tirzepatide, Eloralintide
- Where
- 3 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eli Lilly and Company
Osteoarthritis
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee…
- Trial name
- ATTAIN-OA PAIN (NCT07153471)
- Testing
- Orforglipron
- Where
- 88 sites in United States, Canada and 5 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
Diet; Deficiency
Cross-sectional Dietary Intake Survey on Ivorian School-Aged Children and Women of Reproductive Age
A cross-sectional dietary intake study was conducted with 423 Ivorian school aged children (SAC, 6-12 years) and 423 women of reproductive age (WRA, 15-49 years) from four cities, recruited by two-stage random sampling.
- Trial name
- AN (NCT06175130)
- Where
- Netherlands
- Volunteers
- 846 people, healthy volunteers welcome
- Sponsor
- FrieslandCampina
Overweight, Obesity
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received…
- Conditions
- Overweight, Obesity, Hypertensive
- Trial name
- NCT07469800
- Testing
- IBI362
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.